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Abstract 
Nanoparticle (NP) based systems have advanced the efficacy of treating cancer by enabling 
selective accumulation of drugs in tumors. Photodynamic therapy (PDT) is an exceptionally 
promising modality for its triple selectivity in treating cancer: requiring light, oxygen, and a 
photosensitizer (PS). The choice of a PS can become important not only for its absorption 
spectrum but also its relative aggression in causing oxidative stress; clinicians may prefer one PS 
over another depending on the type of response required to elicit optimal treatment. We show in 
Chapter 2 using polyacrylamide (PAAm) hydrogel NPs that chlorin e6 (Ce6) is a much more 
aggressive PDT agent than the classically applied methylene blue (MB). In addition to 
understanding the relative aggression of a PS in PDT, design of the NP is important to 
optimizing both the reactive oxygen species (ROS) producing capabilities and the means of 
effective delivery. Previously reported 8-arm polyethylene glycol amine (8PEGA) has been used 
to stop heart arrhythmia via PDT from conjugated Ce6. This NP is ideal for also targeting cancer 
due to the optimized ROS production, ease of changing targets, and its small size that would 
allow for deep tumor penetration in vivo. In Chapter 3, the tumor targeting peptide F3-cys was 
successfully grafted to 8PEGA-Ce6 and cancer cells efficiently ablated in vitro, demonstrating 
promise in translation to cancer in vivo. In addition, 8PEGA was shown to be a very promising 
diffusion weighted magnetic resonance (MR) imaging agent for cancer due to its long T2 lifetime 
and high molecular weight. 8PEGA may then potentially act as an efficient agent in MR of 
tumors in vivo without the use of toxic heavy metal atoms. Lastly, while NP-mediated PDT has 
been efficiently described in treating cancer and stopping heart arrhythmia, it may also be 
 xi 
 
suitable to treating cancer-like diseases, such as choroidal neovascularization (CNV). In Chapter 
4, the FDA-approved dyes indocyanine green (ICG) and the PS verteporfin (VP) were 
successfully encapsulated in pluronic micelles and shown to ablate cancer cells with low inherent 
toxicity. Given the cancer-like nature of CNV, NP-mediated PDT looks like a potential modality 
for treatment.  The presented systems are effective in evaluation of their objectives and should 
further encourage clinical adoption of NPs for theranostics (PDT + imaging) by being simple to 
prepare, purify, and exceptionally biocompatible. 
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Chapter 1: Introduction 
1.1 A brief history of PDT 
Photodynamic therapy (PDT) is the process by which biological material is ablated via 
oxidative stress. The first evidence of this process was reported by a Dr. Hermann von Tappeiner 
of Germany when attempting to treat various skin conditions using light. He observed that a 
combination of a photosensitizer (PS), oxygen, and light would yield a reaction in the skin 
conditions, which he later coined “photodynamic action” in 1904.1 
In 1948, Figge and co. discovered that porphyrin dyes (a class of dyes known to be PSs) 
had an affinity for accumulating in rapidly dividing cells.2 Based on this, the hypothesis that 
PDT could be used to treat cancer began to take substantial shape within the scientific 
community. Thomas Dougherty and co. of the Rosewell Park Cancer Institute clinically tested 
PDT in 1978, where they showed substantial success in their preliminary work; 111 of 113 
malignant tumors tested displayed either total or partial resolution.3 The dye employed by 
Dougherty, known as HpD, became the first clinically approved dye for PDT in 1993, under the 
brand name Photofrin, for treatment of bladder cancer in Canada. Their work was essentially 
limited to near surface tumors, where visible photons are not significantly absorbed or scattered. 
In more recent years, a substantial degree of effort has been put towards refining the PDT 
methodology for non-superficial application.4 PDT has shown great promise using Photofrin, but 
there remains substantial work to be done in reconciling this modality against the inherent 
problems of tumors in biological models (e.g. non-specific PS interactions with blood proteins, 
tissue hypoxia, lack of active PS targeting).3 
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1.2 Inherent Problems of Dyes in PDT 
The first and most apparent problem in the viable application of PDT in vivo is the lack 
of targetability and stability of dyes suitable to function as PSs. PSs chosen for use in vivo are 
non-toxic in the absence of light, but do not naturally accumulate in tumor cells, are rapidly 
scavenged by the immune system, and in some cases, such as methylene blue’s, are reduced in 
the blood, resulting in their loss of photodynamic activity.5,6 
Photosensitizers have been attached directly to targeting agents (peptides7,8 and 
antibodies9,10) that are tooled to bind and enter specific cells. This is advantageous as a general 
application for PSs by: 1) triggering cell uptake of a PS and 2) causing the uptake of a PS to be 
selective towards cancer cells. However, this method is not viable for PSs, such as methylene 
blue,11 that are susceptible to reduction by blood enzymes. This method is further complicated by 
a need to preserve the structure of a targeting agent when modifying it, to maintain its cell 
specificity, and the difficulty in purifying targeted materials of free PS. In addition, antibodies 
specifically are exceptionally expensive, and so those alone do not represent an economically 
viable application of PDT. Nanoparticle (NP) based systems therefore represent a more viable 
method of delivery of PSs for cancer PDT in vivo. 
 
1.3 Nanoparticles as Solutions of Inherent Problems in PDT 
One of the earliest engineered NPs was reported by the Kopelman lab, where it was 
shown that NPs (coined as nano-PEBBLES at the time) can function as efficient vehicles for 
delivery of dyes to cells for a variety of applications.12 This pioneering work was later extended 
for cell-targeted PDT in cancer.5,13 Shortly thereafter, it was also shown that using these NP-
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based systems offered the advantage of protecting the PS methylene blue from blood enzyme 
reduction, indicating that NPs are capable of protecting a PSs photoactivity in a biological 
environment.6 Following the initial work using silica and polyacrylamide (PAAm) based 
PEBBLES in the Kopelman lab, a wide range and variety of NPs have been produced and tested 
for delivery of a PS, such as: silica gel,14 poly-(lactic-co-glycolic acid),15 keratin,16 self-
assembled proteins,17 and noble metal NPs.18  
Silica gel can be considered the classical example of NPs in PDT application due to being 
the earliest known report.5 Silica gel is a highly stable material, resistant to breakdown in 
biological systems, and may efficiently encapsulate a PS during synthesis.13 However, silica gel 
is also a very dense material, offering little in the way of porosity, inherently leading to lower 
PDT viability by limiting oxygen diffusion within the matrix.13 These limitations have been 
improved upon by generating meso-porous silica gel nanoparticles, leading to significantly better 
oxygen diffusion and thus PDT performance.19 However, silica gel NPs suffer from low renal 
clearance kinetics due to their stability.20 NPs more likely to be FDA-approved would ideally 
decompose more quickly in the filtration organs. 
PAAm hydrogel is the succeeding material to silica gel in targeted NP-PDT. These NPs 
are simple to prepare, purify, and may be loaded with any PS one may desire at necessary 
concentrations.6 Additionally, covalent linkage and encapsulation leads to increased photo-
stability by limiting solvent effects and preventing dye aggregation/leakage. These NPs are also 
composed of crosslinkers that enable their controlled biodegradation, allowing for significantly 
quicker body clearance.21,22 Polyacrylamide displays superior PDT efficacy when compared to 
silica gel due to being significantly more porous.13 It represents the first material to accomplish 
targeted PDT that may be non-superficially applied to animals.  
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Noble metal nanoparticles, specifically gold, have also been examined as vehicles for 
PDT. Gold is generally considered to be a non-toxic substance, has a well understood surface 
chemistry for modification, and may enhance PDT properties of a PS.23 Gold (Au) NPs may also 
renally clear the body efficiently if engineered correctly.24 However, AuNPs are limited purely to 
their surfaces in terms of modification, meaning that there is a significant limit to the amount of 
PS that may be loaded, and the PS used may not be segregated from the local biological 
environment. In addition, AuNPs can be efficient fluorescence quenchers, and thus if not 
engineered carefully will diminish or prevent PDT.23 
8-arm polyethylene glycol amine (8PEGA) has also been successfully used as a 
nanocarrier in PDT for the stopping of heart arrhythmia by ablating cardio-myocytes.25 It was 
shown that the attachment of the PS chlorin e6 (Ce6) to 8PEGA significantly improved PDT 
efficacy by 50% when compared to the free PS.26 The 8PEGA was also shown to be targetable, 
cell-selective, and capable of penetrating dense tissue due to its small hydrodynamic volume. 
Additionally, though this has yet to be explored, its small size may allow for rapid renal 
clearance. However, the small size may yet present a challenge in cancer application due to 
tumors having a positive pressure, known to prevent significant entry of chemodrugs.27 
Clearly, there are limits and advantages to using certain NP constructions. This should be 
expected however, as different biological conditions will necessitate meeting different 
requirements. There should not be any NP construction thought of as ‘universal’, though it would 
not be unlikely to see constructions that can be applied to multiple situations. 
In addition to the transport of PSs for delivery to cancer cells, NPs also benefit from the 
enhanced retention and permeability (EPR) effect, where they tend to accumulate within the 
tumor area due to its anomalous vasculature.27  
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NPs thus have the tendency to enable the protected delivery of a PS to a cancer cell for 
PDT, preserve its photoactivity by excluding PS interactions with the blood enzymes, and by 
extension, increase its blood circulation time in vivo. However, this still leaves the issue of 
targeting, a two-fold issue. 
The first issue with NPs is that without any targeting, they, like the PSs, hold no affinity 
to any specific cell type. The second issue is that NPs will experience non-specific protein 
adsorption to their surface (surface fouling), resulting in a loss of blood circulation time due to 
scavenging by blood macrophages and immune cells (though they do overall represent a net 
increase in blood circulation time for the PS than without the NP present).28 Both of these 
problems can be overcome by applying PEG. 
PEG has been shown to be a very good substance for disguising NPs from the immune 
system and preventing surface biofouling.29 NPs (silica, polymeric, and otherwise) are typically 
functionalized with various primary amine containing groups for the wide range of modification 
chemistry this allows. These can be used to graft linear PEG onto their surfaces, resulting in a 
substantial improvement of blood circulation time. Noble metal NPs may also be functionalized 
with PEG by taking advantage of their well understood surface chemistry. Additionally, linear 
PEG is available as a heterofunctional moiety, allowing for the other end that is not mounted to 
the NP surface to be used as a molecular anchor for targeting agents to the NPs.30 Thus, NPs may 
be cell-specific targeted and achieve long blood circulation time, increasing the accumulation of 
a PS in the tumor area. 
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1.4 Biological Challenges in PDT Application 
The above thus sufficiently addresses the first problems with achieving non-superficial 
(effective and cell-selective) application of cancer PDT in vivo. The second issue to be addressed 
is maximizing the efficacy of PDT. This is critical because advanced tumors are hypoxic in 
nature.31 PDT relies on the destruction of cancer cells via oxidative stress produced by reactive 
oxygen species (ROS), resulting through reaction with the local oxygen; thus, it becomes 
especially important that PDT is applied in such a way as to maximize its effects.32 The relative 
hypoxia of a tumor based on distance from vasculature as a result of proliferation is shown in 
Figure 1-1.33 
 
Figure 1-1: Tumor hypoxia as a result of unchecked tissue growth. A) Cartoon of tumor cell 
proliferation with respect to vasculature proximity. B) Quantification of tumor oxygenation with 
respect to vasculature proximity; Dotted line = extracellular pH, Dashed = tumor oxygenation. 
Reproduced from reference 33. 
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As was explored before, a PS is encapsulated in NPs to protect them during delivery to 
the sites of interest for a given application. This will lead to a decrease in ROS production over 
the free dye because oxygen must diffuse into the housing matrix and ROS diffuse out without 
attacking that matrix. One method of maximizing this ROS production is to tailor the NP matrix 
to be especially porous.34 This leads to more efficient usage of the ROS, enabling greater 
efficacy in a hypoxic environment. 
Another explored method is to drag oxygen into the tumor cells by using nanodroplets of 
perfluoronated materials. Perfluorocarbons (PFC) are biologically safe materials that have 
exceptional oxygen solvation properties and so are desirable to be incorporated into NPs, 
whereby they may mediate the PDT, avoiding reliance upon the biologically present oxygen.35 
Unfortunately, a majority of PFCs are hydrophobic, limiting their applications in biological 
systems. Micelles or liposomes make excellent carriers for hydrophobic materials, allowing for 
their dispersion in aqueous media. A phospholipid that incorporates perfluorohexane into its core 
as a nanodroplet has been recently reported where it increased both radiation therapy and PDT 
efficacy.36,37  
Thus, hypoxia in tumors can be addressed as a PDT limitation through suitable synthetic 
designs and material choices. The final limitation that must be considered when applying PDT to 
a tumor is its physiology. In its most basic form, a tumor can be described as a de-regulated 
growth of a cell population. Under such conditions, they will eventually approach the point of 
nutrient deficiency. When this point is reached, there are two possible outcomes: angiogenesis or 
cells switching to anaerobic glycolysis.38-40  
For the cells that undergo anaerobic glycolysis, they will eventually die as tumor progress 
leads to further nutrient deficiencies. However, the tissue that experiences angiogenesis to form 
 8 
 
new leaky vasculatures will support the continued growth of cancerous tissue. NPs take 
advantage of the leaky nature in the cancerous vasculature through the EPR effect to 
accumulate.41,42 Since the coining of angiogenesis in 1971, it has largely been assumed that 
tumors grow exclusively through this method. As a result, vascular targeted PDT (VPDT) has 
become a topic of focus in treating cancer.43,44 
However, it has recently been reported that tumor growth is supported by a combination 
of angiogenesis and healthy vasculatures.45,46 This raises the problem of NPs being able to 
adequately treat certain types of cancer that may have low angiogenic expression. To our 
knowledge, no work has been done towards expressly exploring this, making exploration 
appealing for: 1) evaluating how NP systems must change to ensure tissue penetration and 2) re-
evaluate the depth to which hypoxia may fluctuate and affect PDT efficacy.47 
Irrespective of the anomalous nature of tumor structuring, like any healthy tissue it may 
limit optical transparency. This can be overcome to a certain extent by designing fiber optic 
systems that allow for adequate illumination of PSs to initiate PDT treatment,48 but it is always 
desirable to use long wavelength, near infrared active dye moieties, due to the greatly reduced 
tissue light scattering and absorption in these spectral regimes.  
The greatest tissue penetration of light capable of exciting molecular electronic 
transitions for ROS production occurs at what is known as the first optical window, ranging from 
650 – 950nm (Figure 1-2).49,50  
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Figure 1-2: Various contributions to optical density by tissue in vivo. HbO2 = oxy-hemoglobin, 
HbR = deoxy-hemoglobin, MbO2 = oxy-myoglobin, MbR = deoxy-myoglobin. Reproduced 
from reference 50. 
There is a severe lack of dyes that efficiently produce ROS with absorption located in this 
range. Indocyanine green (ICG) and NIR783 have been shown to be capable of PDT but require 
high laser powers due to their low ROS production.51,52 Another method of realizing deeper 
penetrating PDT is the use of upconverting nanocrystals.53,54 However, upconverting 
nanocrystals are typically made of rare-earth materials and suffer from low brightness (causing 
low PDT viability).55 
 
1.5 Overview of Dissertation 
The aforementioned topics clearly show that PDT is a highly viable method of controlled 
and precise cancer ablation, owing to its four-fold selectivity (requires light, oxygen, PS, and can 
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be targeted using NPs with peptides/antibodies). However, to realize a successful extension of 
PDT to subsurface tumors in the clinical setting there is still much work to be done in refining 
designs towards such applications. 
While design of NP matrices is important to the evaluation of systems for viable PDT, the 
choice of PS also plays a significant role. Unfortunately, there is no library of data that 
thoroughly evaluates the relative efficacy of PSs in NP-PDT. Therefore, Chapter 2 places 
emphasis on investigating relative PDT effectiveness of two commonly employed PSs: 
methylene blue and chlorin e6. Both PSs are encapsulated in PAAm hydrogel NPs and their 
relative effectiveness at ablating cancer cells under identical illumination conditions are 
compared when correlated against their absorption properties. 
In Chapter 3, the focus of the work is primarily on development of a peptide-polymer-PS 
conjugate, F3-8PEGA-Ce6, that is suitable for deep penetration of cancerous tissue, optimization 
of ROS production, and efficacy as an magnetic resonance (MR) imaging agent. The ROS 
production was compared against the traditional PS encapsulated PAAm model. Penetration of 
dense tissue with 8PEGA-Ce6 has previously been reported,25 and the successful modification of 
the nanoplatform with another targeting agent indicates extension of application for 8PEGA-Ce6 
as a whole to other biological areas of interest for PDT. 
Lastly, while cancer has been the focus of this discussion, there do exist other biological 
abnormalities and conditions that resemble cancer to a remarkable degree, such as choroidal 
neovascularization (CNV). There are currently no cures for CNV, but there does exist an FDA-
approved procedure of PDT.56 However, a lack of cell specificity can cause severe side effects 
(secondary CNV or coronal atrophy),56 and almost no literature exists on refining this. Chapter 4 
therefore focuses on the refinement of PDT for CNV to suitably treat the condition by 
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encapsulating the FDA-approved dyes Verteporfin and ICG in micelles, testing their PDT 
efficacy and toxicity towards significantly improved cell specificity in CNV oriented PDT. 
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Chapter 2: Intracellular Activity of Chlorin e6 Containing Nanoparticles 
2.1 Introduction 
The following results are published in the International Journal of Nanomedicine and 
Nanosurgery.1 
Cancer is a leading cause of death in the US, with treatment being limited to non-
selective methods, such as chemo, radio therapy, and surgery.2 This has led to expansive interest 
in researching selective therapeutic methods to increase survival rates and general quality of life. 
The use of targeted nanoparticles (NPs) has been one approach.2-4 
Hydrogel NPs have been shown to accomplish a variety of tasks in cancer treatment, such 
as imaging,5 visible tissue delineation,6 selective accumulation of chemo drugs,7,8 photo-dynamic 
therapy (PDT),9 photo-thermal therapy (PTT),10 and sensing.11 Each role is important either for 
probing the micro-environments of tumors to determine the most effective methods of treatment 
or enabling treatment. Specifically, PDT enjoys a vast quantity of interest due to its extreme 
selectivity and inherent lack of resistance from tumors. 
PDT is the production of cytotoxic reactive oxygen species (ROS) when certain dyes 
(photosensitizers, PS) are excited under photo-illumination in the presence of oxygen. Therefore, 
PDT requires light, a PS, and oxygen to elicit cytotoxic effects. When combined in NPs that have 
been surface modified (peptides, antibodies, small molecules, etc.) to be cell-specific in uptake, 
extreme selectivity in treating cancer cells is achieved through selective accumulation.  
Multiple photosensitizers capable of PDT have been employed (e.g. Photofrin, methylene 
blue, chlorin e6), but their relative aggressions in treating cancer using NPs are not well 
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characterized. Chlorin e6 (Ce6) has been used for therapy of both cancer and heart disease.11-16 
Here, we study the relative efficacy of Ce6 and methylene blue (MB) in vitro, when embedded in 
hydrogel polyacrylamide (PAAm) NPs, to evaluate their relative aggression in treating cancer. 
Previously reported MB-NPs are used for comparison.17 
 
2.2 Results 
2.2.1 Covalent Encapsulation of Ce6: Ce6 contains three aliphatic carboxylate groups that 
make it possible for the covalent attachment of the dye to our NPs. Covalent anchoring to the NP 
matrix is accomplished through the typical EDC/NHS reaction to primary amine containing 
monomers, which is then subsequently polymerized with the remaining monomers to form the 
hydrogel NPs. UV/VIS of the purified particles is presented in Figure 2-1; the canonical peak at 
663nm is present. 
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Figure 2-1: UV/VIS spectra of as prepared PAAm-Ce6 NPs at 1mg/mL in PBS. The soret band 
at ~400nm that is typical to porphyrins is omitted due to saturation of the detector. 
 In addition to the UV/VIS spectra, excitation and emission spectra are taken to show that 
that photo-physical properties are left unaffected (Figure 2-2). Fluorescence spectra was taken 
using the 663nm peak. However, because of the characteristic small stokes shift of porphyrin-
based dyes (~1-2nm), the fluorescence peak is marginally clipped to avoid the detector picking 
up part of the excitation signal. It can be seen in Figure 2-2 that the Ce6 is still fluorescent and 
that the excitation spectra reflects the absorption spectrum of Figure 2-1. 
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Figure 2-2: Ex/Em spectra of the as prepared PAAm-Ce6 NPs. The particles were dispersed in 
PBS at a concentration of 0.1mg/mL to avoid detector saturation. Excitation = Blue, Emission = 
Orange (663nm Ex). 
 In addition to the photo-physical properties of PAAm-Ce6, the general size of the NPs 
must be characterized to aid in evaluation of any toxicity data. Typically, dynamic light 
scattering (DLS) is employed as a method of characterizing hydrogel NPs, but the light source of 
these instrument is ~658nm. Due to this, characterization of PAAm-Ce6 NPs via DLS is not 
possible with the dye present. As an analogue method of analysis, NPs without Ce6 were 
synthesized. The size is found to be ~73nm (Figure 2-3). 
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Figure 2-3: DLS of hydrated blank PAAm NPs. Mean diameter = 73nm, PDI = 0.204. 
 Transmission electron microscope (TEM) images of the PAAm-Ce6 NPs were also taken 
to provide a more direct understanding of the NP size (Figure 2-4). The size of these NPs is 
found to be ~17nm when dehydrated, similar in size to previously reported MB-NP TEMs 
(~14nm). 
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Figure 2-4: TEM images of dehydrated PAAm-Ce6 NPs. NPs were vacuum deposited onto the 
grid due to low adherence properties of hydrogel polymers on TEM grids. 
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2.2.2 ROS Generation in Solution: It is important to evaluate that Ce6 is still producing singlet 
oxygen. Although the preserved absorption and fluorescence properties indicate a preservation of 
ROS producing capabilities, it is important to note that Ce6 is still specifically producing type II 
ROS (singlet oxygen) and has not changed to predominantly producing type I (all other known 
species). To accomplish this, singlet oxygen sensing green (SOSG) is employed; SOSG 
specifically evaluates the presence of singlet oxygen and is insensitive to all other forms of ROS. 
Figure 2-5 shows a clear fluorescence enhancement of SOSG after illumination at 663nm in the 
presence of PAAm-Ce6 NPs. 
 
Figure 2-5: SOSG fluorescence before (0 seconds) and after a period of 663nm illumination (300 
seconds) in the presence of PAAm-Ce6 NPs. The peak at ~665nm comes from Ce6. 
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2.2.3 In vitro PDT Efficacy: Before PDT testing of the PAAm-Ce6 NPs can be initiated, it is 
important to first test if there is any toxicity from the NPs alone with no illumination. To this 
end, HeLa cells are incubated with PAAm-Ce6 NPs overnight and evaluated using MTT assay. 
The results are shown in Figure 2-6; no significant toxicity is observed. 
 
Figure 2-6: Dark toxicity of HeLa cells incubated with PAAm-Ce6 NPs overnight. Cells exposed 
to 200ug/mL were 89% viable. 
 Following establishing biocompatibility of the PAAm-Ce6 NPs their PDT efficacy was 
evaluated on a 96-well plate of HeLa cells with an LED array (625 +/- 20nm, 35.2mW). Using a 
dosage of 200ug/mL and 6min illumination, ~42% of the cells are killed (58% viable, Figure 2-
7). 
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Figure 2-7: HeLa cell viability after PDT (6min, 625 +/- 20nm, 35.2mW). Cells incubated at 
200ug/mL are ~58% viable post treatment. 
 Further analysis of PAAm-Ce6 NPs in PDT is done in comparison to previously reported 
MB-NPs. The relevant properties for discussion are shown in Table 1. 
NPs Wt% 
Loading 
nmol 
dye/mg NP 
Loading 
TEM (nm) NP OD @ 
~625nm 
6min PDT 
Viability 
Ce6 1.40 23.4 17 0.2 58% 
MB 0.63 13.1 14 0.5 70% 
Table 2-1: Comparative Data of Ce6 and MB-NPs.17 OD = Optical Density at peak wavelength 
of light source, NP concentration = 1mg/mL. Note: Same light source and configuration used for 
both photosensitizers. 
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2.3 Discussion 
 A main feature of free Ce6 in aqueous and saline solutions is its tendency to aggregate. 
NPs generally act as an efficient means of reducing or eliminating aggregation by forcefully 
separating dye molecules from each other. Figures 2-1 and 2-2 show no signs of Ce6 aggregation 
via preservation of its 663nm peak and fluorescence. This is further reinforced by SOSG 
showing continued singlet oxygen production (Figure 2-5). 
 NPs may often be a source of toxicity in cells. This is typical in one of two ways: being 
overly positively charged (e.g. PAMAM dendrimer) or being too large. To evaluate the size of 
the NPs, DLS and TEM were employed. DLS of blank NPs (no dye, Figure 2-3) were ~73nm 
and TEM showed a size of ~17nm (Figure 2-4), similar to the as compared MB-NPs.17 
Therefore, the size of the PAAm-Ce6 NPs is within a biocompatible range. Dark toxicity of the 
PAAm-Ce6 NPs (Figure 2-6) confirms this by the low toxicity at a high concentration of 
200ug/mL. 
 PDT of HeLa cells with PAAm-Ce6 NPs yielded a cell kill of 42% (Figure 2-7). This is 
remarkable when compared to previously reported MB-NPs under the same illumination 
conditions that aimed to optimize the production of ROS; the MB-NPs yielded a cell kill of 
30%.17 A difference of 30% vs. 42% may seem insignificant, but the meaning becomes more 
pronounced when the relative absorption spectra of the NPs is factored in. The PAAm-Ce6 NPs 
have an OD of 0.2 vs 0.5 for the MB-NPs at identical concentrations of 1mg/mL; the MB-NPs 
were less efficient at ablating cancer cells than the PAAm-Ce6 NPs while being ~2.5 times more 
absorbant in the range of active illumination. This overwhelmingly indicates that Ce6 is a more 
efficient dye for PDT than MB in NP-based systems. 
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 It is also worth noting the shortcomings of the as presented system. The primary issue 
faced with the NPs is the diminished hydrophilicity with increasing Ce6 loading. This is not 
entirely unexpected, as the hydrophilic groups of the dye are co-opted for covalent attachment. In 
this aspect, MB is a more desirable dye due to its exceptionally higher aqueous solubility. The 
lowered solubility of the PAAm-Ce6 NPs would also decrease their overall efficacy in vivo, 
where high administration dosages of 20-50mg/mL are necessary. Optimization of dye loading, 
matrix design, and synthetic conditions will likely yield NPs with greater hydrophilicity and thus 
animal model viability. 
 
2.4 Conclusions 
 The PS Ce6 was successfully encapsulated in a PAAm hydrogel through standard 
EDC/NHS coupling reaction while preserving its basic photo-physical properties. The as 
prepared PAAm-Ce6 NPs displayed low toxicity in the dark at a high concentration of 200ug/mL 
and greater in vitro PDT capacity than previously reported MB-NPs. It is therefore understood 
that the PS Ce6 is a superior candidate in NP-PDT when compared the classical golden standard 
PS MB. 
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2.6 Materials and Methods 
Materials: All materials were sourced from Sigma Aldrich. acrylamide (AAm), amino 
propyl methylacrylamide (APMA), 3-(acryloyloxy)-2-hydroxypropyl-methacrylate (AHM), 
dioctyl sulfosuccinate sodium salt (AOT), Brij 30, 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC), N-hydroxy succinidmide (NHS), dimethyl sulfoxide (DMSO), phosphate 
buffer saline (PBS, 0.01M), ammonium persulfate (APS), tetra methyl ethylene diamine 
(TEMED), phosphate buffer saline (PBS). 
Preparation of PAAm-Ce6 NPs: 1.07g of AOT, 2.2mL Brij 30, and 30mL Hexane are 
combined in a 100mL round bottom flask. An aqueous phase of 28mg APMA, 368mg AAm, 
52.6uL AHM, 40mg EDC, 60mg NHS, 100uL DMSO, and 930uL PBS are prepared and added 
to the round bottom flask. The contents of the flask are stirred for 2 hours at 500 RPM. The 
contents are then flushed with argon using a long neck needle in contact with the mixture for 15 
minutes. Argon flow is then continued but removed from contact with the mixture. 15mg of APS 
in 100uL of water is added drop wise to the flask to initiate polymerization. 100uL of TEMED is 
added drop wise and the reaction allowed to continue for 2 hours under argon. Argon is then 
removed, and the contents of the flask exposed to oxygen to quench polymerization. Hexane is 
rotary evaporated, and the leftover contents are cleaned in an amicon cell (300kDa membrane) 
with 10x150mL ethanol and 5x150mL Millipore water. The final product dispersed in Millipore 
water is filtered using a 0.45um polyether sulfonate filter and lyophilized to obtain a solid 
product. Samples are stored in a freezer until needed. 
Singlet Oxygen Test: ROS production was tested using Singlet Oxygen Sensing Green 
(SOSG). A 1mg/mL sample (2mL, PBS) was given 10uL of 0.5mM SOSG in methanol and 
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illuminated at 663nm for 5min. The fluorescence of SOSG was measured at 504/525nm Ex/Em 
before and after illumination. 
Size analysis: TEMs were taken through the Microscopy and Image Analysis Laboratory 
at the University of Michigan. Samples were deposited on grids via vacuum evaporation of 
solvents and subsequent staining with uranyl acetate. Blanks of NPs (no dye) were synthesized 
and characterized using dynamic light scattering (DLS, Delsa Nano C Particle Analyzer). 
Photo-Physical Properties: Absorption spectra were gathered using a Shimadzu UV-
1601 UV-Visible Spectrophotometer and all fluorescence-based work done using a Fluoromax 3. 
Cell Culture: 96-well plates were seeded with 2000 HeLa cells per well (n = 16) 
containing 200uL of media. Plates of light and dark toxicity were given NP dosages of 0 and 
200ug/mL; 0 ug/mL were control groups that defined 100% viability. Cell viability was 
determined colorimetrically in a plate reader via MTT assay. Briefly, cell media was replaced 
with colorless media containing no serum (100uL) and 20uL of 5mg/mL MTT reagent and 
incubated for 4 hours. The media was then carefully removed and the formazan crystals 
solubilized using 100uL of DMSO. Light toxicity was investigated by illuminating the 96-well 
plate using an LED array (625nm +/- 20nm, 35.2mW) for 6min. 
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Chapter 3: An Ultra-Compact Nano-Theranostic PEG Platform for Cancer and Heart 
Arrhythmia 
3.1 Introduction 
The following is currently in submission to ACS Applied Bio Materials.1 
We describe here a multi-functional, ultra-small, nanoplatform that has a plethora of 
desirable therapeutic and diagnostic (theranostic) properties. Specifically, we demonstrate its 
superior photodynamic efficacy, illustrated by its application to cancer cells. We also emphasize 
its unique performance as an excellent, non-toxic, molecular imaging agent for MRI. 
Photodynamic therapy (PDT) is a method for ablating biological tissue by photo-
oxidation utilizing photosensitizer (PS) molecules. PDT has been pioneered by Dougherty and 
co. at the Roswell Park Cancer Institute for treatment of skin cancer and other diseases.2,3 Since 
the start of the millennium, the field has received additional attention due to the emergence of 
cell-targeted PDT. Both spatial (laser focused) and biological (cell selective) selectivity is 
achieved by employing nanoconstructs (NCs) with targeting antibodies or peptides, which also 
extended PDT treatment to subsurface tumors.3-9 In general, the use of NCs allows for protection 
of a PS from the bio-environment, and vice versa, for bypassing the immune system4-13  
Recently, we reported on the use of PDT for treating heart arrhythmia in rat and sheep 
models.14 The NC utilized was the octopus-like, ultra-compact and highly biocompatible 
polymer, 8-arm polyethylene glycol amine (8PEGA). The amine terminated arms were used to 
anchor the algae derived PS, chlorin e6 (Ce6), and a targeting moiety for cardio-myocytes.14 
Here, the relatively small sized (<20nm) 8PEGA derived NCs penetrated the very dense tissue of 
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the heart muscle, selectively accumulating in cardio-myocytes, and thus allowing their 
photodynamic ablation under mild near infrared illumination. Given the success of cell-selective 
heart arrhythmia ablation, we focus here on adapting an analogous NC for treating cancer.  
In the heart arrhythmia project, the method of tagging 8PEGA with CTP (cardiac 
targeting peptide) for targeting was the very well understood maleimide-thiol reaction. Similarly, 
we expect any peptide to be viable for attachment 8PEGA, provided it is cysteine terminated. 
The F3-cys peptide is a specific cancer targeting peptide studied by our lab at great length.9,15 It 
was thus chosen as our test case for extending the application of 8PEGA-Ce6 from arrhythmia to 
cancer. HeLa cells were chosen as the model system of interest due to their robust nature and 
known over-expression of nucleolin,16 the specific target of the F3-cys peptide.15 While our 
initial interest in 8PEGA stemmed from its small size, (sufficient to penetrate heart muscles) and 
its biocompatibility, in this work we focus on: 1) its ability to optimize ROS production with a 
given PS, and 2) its ability to function as a molecular imaging agent for MRI. The optimized 
ROS production is expected for this NC due to the direct contact of the PS Ce6 with the 
oxygenated environment, in contrast to when it is encapsulated inside a standard model matrix, 
such as in Polyacrylamide hydrogel nanoparticles (PAAm NPs).17 We demonstrate here an 
increased ROS production efficacy, biocompatibility, and flexibility in targeting when utilizing 
this NC. 
The high molecular weight (40 kDa), flexible chain dynamics of the 8PEGA group, and 
its specific structure, also create favorable conditions for highly selective molecular imaging 
using MRI. Specifically, the slow diffusion constant and transverse spin relaxation rate of 
8PEGA combine to allow diffusion weighted MRI sequences which suppress surrounding water 
and fat signals, providing a very clean image of 8PEGA. We show here that the 8PEGA MR 
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signal is selectively detected and is proportional to its concentration. We also emphasize its 
biocompatibility, compared to current heavy metal atom MRI imaging agents.  
 
3.2 Results 
3.2.1 Complete 8PEGA Characterization: We compared the ROS production of Ce6 when 
attached to 8PEGA vs. when encapsulated in polyacrylamide (PAAm), where the two competing 
nanostructures are represented in Figure 3-1. Figure 3-2 contains the “k-value” plot of the 
relative ROS production of PAAm encapsulated Ce6. The k-value is a measure of the kinetic rate 
at which ROS is produced by Ce6, as measured by the first order decay of ADPA fluorescence. 
While the k-value of 8PEGA was determined by us before,14 to generate k-values that are 
comparable, the OD of the PAAm-Ce6 NPs17 was adjusted by UV/VIS to the Optical Density 
(OD, 0.12) of the previously reported 8PEGA-Ce6 at 660nm.14 Table 3-1 shows the relative 
results for the two NCs when normalized for their literature ODs. 
 
 
Figure 3-1: Difference in structural representation of Ce6 delivery and ROS production efficacy 
(not drawn to scale). Left: basic Jablonski diagram of how ROS is produced by Ce6. Right: 
Encapsulated Ce6 vs anchored to 8PEGA; difference in how ROS may move show a clear 
change in efficacy. 
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Figure 3-2: k-value plot of Ce6 encapsulated in PAAm NP as tracked by ADPA fluorescence 
quenching over time. The 660 nm OD = 0.12 in PBS; the slope of the plot is the k-value. 
Nanoplatform OD k-value 
8PEGA-Ce6 0.12 2.99E-04 s-1 
Ce6/PAAm NP 0.12 1.94E-04 s-1 
Table 3-2: k-values of the two discussed NCs at OD = 0.12 for 660nm. 
Figure 3-3 is a wet transmission electron microscopy (TEM) of 8PEGA on a copper grid that has 
been negative stained with uranyl acetate. The size of the 13 measured NCs is found to be 
consistent with a ~10 – 12nm range, matching the Stokes-Einstein approximation (calculated in 
section 3.2.4) of the material. 
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Figure 3-3: TEM of 8PEGA negatively stained with uranyl acetate. 
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Figure 3-4 shows the absorption spectrum of the F3-8PEGA-Ce6 conjugate; we find that the 
characteristic peaks at 660 nm are preserved, compared to the non-targeted NCs.14 For clarity, 
the chemical modification of 8PEGA-Ce6 with F3-cys is shown in Scheme 3-1. 
 
Scheme 3-1: Modification of 8PEGA-Ce6 with F3-cys peptide, as reported in this paper. 
 
Figure 3-4: UV/VIS spectrum of 8PEGA-Ce6 and F3-8PEGA-Ce6 in PBS at 0.1 mg/mL. 
 
3.2.2 Dark Toxicity of HeLa 229 cells: Flow cytometry was employed as a method of testing 
the biocompatibility of this NC to test for dark toxicity. Cells were tested at a concentration of 
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200ug/mL F3-8PEGA-Ce6; control cells denote a data group with no F3-8PEGA-Ce6 NCs 
added. As can be seen from Figure 3-5, no significant toxicity was observed.  
 
Figure 3-5: Hemocytometry Cell Population Results. Incubation conditions: 200 ug/mL F3-
8PEGA-Ce6 for 24 hours in wells seeded with 200,000 cells; N = 3x3 for control and test groups 
(3 plates each, tested 3 times each). Control group of cells contain no F3-8PEGA-Ce6 NCs, 
under the same conditions. The results show near identical cell populations. 
 
3.2.3 PDT Efficacy in vitro: As a control test to eliminate the possibility of simple cell stress 
from the excitation light, HeLa cells without F3-8PEGA-Ce6 were plated and illuminated for the 
same length of time and power as used in PDT for NC-treated cells (50mW/cm2, 10min). After 
illumination (Figure 3-6A, B) there is an insignificant change in cell morphology, no change in 
the cytosolic stain calcein AM fluorescence counts, and no signs of membrane blebbing (a 
hallmark of apoptosis).  
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We observe a remarkable difference in the calcein AM fluorescence after photo-illumination of 
the cells with F3-8PEGA-Ce6 (Figure 3-6C, D). While there was no observable propidium 
iodidie (PI) fluorescence prior to illumination (data not shown), after illumination cell membrane 
impermeable PI can be seen to stain the nuclei of the cells (Figure 3-6E).  
  
  
A 
 
B 
 
C 
 
D 
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Figure 3-6: PDT testing images of HeLa 229 cells. A) Calcein AM fluorescence of PDT control 
cells (no F3-8PEGA-Ce6). B) Calcein AM fluorescence of PDT control cells 2 hours after 
illumination. C) Calcein AM fluorescence of test cells (with F3-8PEGA-Ce6) prior to PDT. D) 
Calcein AM fluorescence of test cells 2 hours after PDT. E) PI fluorescence 2 hours after PDT. 
PDT test plates were incubated with 200ug/mL F3-8PEGA-Ce6 for 2 hours prior to PDT and all 
cells illuminated at a total fluence of 50mW/cm2 for 10 minutes, using a 692 +/- 20nm filter and 
arc lamp. 
 
3.2.4 MRI/NMR Characterization of 8PEGA: The translational diffusion constant, D, and 
relaxation times T1 and T2 of 8PEGA were measured at 25 and 35 °C (Table 3-2). Images in 
solution of 8PEGA (non-modified) were gathered to demonstrate generation of clean images 
when water/fat suppressed (Figure 3-7) and their concentration dependent response (Figure 3-8). 
The response can be seen to be linear with concentration (Figure 3-8), consistent with images 
E 
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gathered with water suppression techniques (Figure 3-7B). Tested concentrations were 0, 2.38, 
4.77, 9.54, and 19.08 mg/mL 8PEGA in H2O. In addition, the Stokes-Einstein equation: 
𝑟 = 𝑘𝑇/6𝜋𝜂𝐷trans 
is employed to calculate the size of 8PEGA to verify TEM results; the diameter is calculated to 
be 10.96nm at 35 °C. 
 
T (°C) T1 (ms) T2 (ms) D (10
-11 m2/s) 
25 791 ± 36 586 ± 24 3.572 ± 0.015 
35 934 ± 72 769 ± 31 4.923 ± 0.018 
Table 3-2: Relaxation times and translational diffusion constant of 8PEGA at 25 and 35 °C 
measured at 16.4 T. Sample is 5mg/mL 8PEGA in 25/75 (V/V) H2O/D2O. 
 
 
Figure 3-7: Diffusion-weighted spin-echo MR images of 8PEGA obtained with b = 108 s/m2 (A) 
and b = 1010 s/m2 (B). The 110 M water proton signal dominates conventional MR images as 
seen in (A) but is suppressed by a factor of 10-10 by imaging at b = 1010 s/m2. The diffusion 
constant of 8PEGA was measured by stimulated echo pulsed field gradient NMR at 25 °C to be 
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3.572 10-11 m2/s, allowing 70% of the initial magnetization to survive at b = 1010 s/m2. The color 
bar in the (B) shows detected concentration of 8PEGA. 
 
Figure 3-8: Concentration dependent MRI signal of 8PEGA. A region of interest (ROI) was 
selected for each of the 5 vials and mean (circles) and standard deviation (error bars) of the 
signal computed. A linear equation was fitted to the 5 measured vials and the result is shown as a 
dashed line. 
 
3.3 Discussion 
We hypothesized that Ce6-8PEGA would be a more efficient ROS producing platform, 
compared to hydrogel NPs, based on the understanding that in 8PEGA the Ce6 group is in direct 
contact with the oxygenated environment of the cells (Figure 3-1). Thus, oxygen does not need 
to diffuse into a PAAm NP matrix encapsulating the PS and the ROS need not diffuse out, nor 
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suffer losses due to reaction with the matrix. The k-value test confirms this hypothesis by 
showing that, when adjusted to identical ODs, the k-value of the Ce6-8PEGA14 is about 50% 
larger than that of the Ce6 encapsulated PAAm NPs (Table 3-1).  
Being that 8PEGA is a star shaped polymer, measurement of its size by the Stokes-
Einstein Equation, which assumes a spherical material shape, is desirable.18 It is found after 
measuring the translational diffusion coefficient, D (Table 3-2), that the size of polymer at 35 
celcius is ~11nm. As a secondary method of analysis, 8PEGA stained with uranyl acetate and 
visualized using TEM (Figure 3-3). The size of the 13 chosen points is found to be approx. 10 – 
12nm, in good agreement with the Stokes-Einstein Equation measurement. 
PEGylating the surface of nanoparticles is often used as a sort of cloak and dagger 
approach, as PEG is largely ignored by the immune system and cells in general.19 Here the 
platform itself is made of PEG only. Thus, a targeting vector is helpful not only for in vivo 
applications but even to accelerate cell uptake in vitro. For cancer targeting, the nucleolin 
targeted peptide F3-cys has been shown to be quite useful and was thus chosen for grafting onto 
the 8PEGA-Ce6.20-23 Notably, after attachment of F3-cys, the Ce6 spectroscopic features are 
largely unaffected (Figure 3-4), indicating the preservation of photophysical properties when 
switching peptides (from CTP for targeting heart myocytes to F3 for targeting cancer cells).14-16 
A mild decrease in Ce6 absorption is noted for 0.1mg/mL when compared to before and after 
modification, but is expected, as the BiPEG and F3-cys will increase the MW of the NC. 
An important aspect of this NC is its biocompatibility. The total construction is 
comprised of PEG, Ce6, and the homing peptide F3-cys. PEG is commonly known as a highly 
biocompatible substance and F3-cys has been used as a targeting agent in our lab and others with 
no toxic effects in vitro or in vivo.20-23 The algae derived Ce6 has been used extensively in the 
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literature as a PDT agent.24-28 As such, it is expected that the combination of these three moieties 
should present no significant biocompatibility issues. This is confirmed in vitro by our 
hemocytometry results (Figure 3-5).  
Before initiating PDT tests with F3-8PEGA-Ce6, the chosen laser conditions (50mW/cm2 
for 10min) were tested to ensure that the illumination was not a source of significant cell stress. 
Calcein AM images of the cells before (Figure 3-6A) and after (Figure 3-6B) illumination 
demonstrated little change in morphology and no signs of apoptosis. Therefore, the photo-
illumination source does not impart significant stress upon the cells. PDT was then initiated in 
the presence of F3-8PEGA-Ce6 at a concentration of 200ug/mL (Figures 3-6C/D/E). There is a 
significant decrease of calcein AM fluorescence after PDT, indicating a loss of cytosolic 
contents, an event that would only occur under conditions where the cell membrane has been 
ruptured. Rupturing of the membrane was shown by the staining of the nuclei with the cell 
impermeable dye PI (Figure 3-6E). Taking the PDT test results in conjunction with the cyto-
compatibility in Figure 3-5, it is evident that the death of the cells is PDT-mediated. 
In addition to the more efficient PDT (50% larger k-value), we believe that the use of 
8PEGA NPs may present two more advantages: (1) The small size of the NC offers the 
possibility of quick renal clearance from the body,14 a feature not afforded by larger NPs, and (2) 
the ability to penetrate tumor areas that have not yet undergone angiogenesis, in contrast to 
traditional larger NPs that require a porous/leaky vasculature so as to be able to penetrate the 
tumor.29  
Previous work has shown that 13C tagged PEG could be selectively imaged in vivo using 
heteronuclear MR methods.30 We report here that the intrinsic flexibility of the polyethylene 
oxide chain31 and the slow translational diffusion of 8PEGA create an exploitable set of physical 
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and dynamic conditions for selective MR imaging of 8PEGA protons using 1HNMR.  
Specifically, 8PEGA’s fast chain motions with correlation times of approximately 0.1ns31 
provide sufficient averaging of the proton dipole-dipole interaction to yield a long nuclear spin 
transverse relaxation time T2, measured here to be 586 and 769ms at 25 and 35 °C, respectively. 
In contrast to fast internal chain dynamics, the molecule’s high molecular weight yields a 
translational diffusion constant that is two orders of magnitude slower than that of water 
molecules. Therefore, the water signal can be effectively suppressed by large diffusion 
gradients32 so that only the ethylene oxide signal will remain due to the combination of its long 
T2 time and slow diffusion if 8PEGA. Notably, the MR signal intensity decays as: 
𝑀𝑥𝑦(𝑏, 𝑇𝐸) = 𝑀𝑥𝑦 (0)𝑒
−𝑏𝐷𝑒−𝑇𝐸 𝑇2⁄  
where the b value is determined by the magnetic field gradient magnitude and duration, D is the 
translational diffusion constant of either water or 8PEGA, TE is the echo time, and T2 is the 
transverse spin relaxation time. In addition, the symmetry of the ethylene oxide monomer gives 
rise to a single chemical shift for all four protons and each 40kDa polymer molecule caries 
approximately 3,600 protons, creating a large molar amplification of the NMR or MRI signal. By 
performing a diffusion-weighted, spin-echo MR imaging experiment with high b values and long 
TE times, water signals, due to fast diffusion, and fat signals, due to short T2 times, are 
effectively suppressed and the 8PEGA signal selectively imaged. In vivo, some signal at high b 
values will remain due to restricted diffusion in cells, but these signals can either be removed or 
distinguished from the 8PEGA signal due to the ~1 ppm difference between water and ethylene 
glycol protons in traditional 1HNMR. 
The results (Figure 3-7A, B) indeed show that 8PEGA functions very well as an MR 
imaging agent when coupled with the above-mentioned suppression techniques. This may 
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potentially replace other MRI contrast agents like gadolinium salts or chelates, which present 
health risks to certain patient groups. There is a clear difference in images without (Figure 3-7A) 
and with (Figure 3-7B) applied suppression techniques. The 8PEGA imaging signal is also linear 
with its concentration (Figure 3-8). Notably, when the above techniques are applied, clean and 
well-defined images of 8PEGA are recovered, showing clearly its viability as a potential imaging 
agent in vivo. If properly calibrated for, this would allow for quantification of the 8PEGA in 
biological tissue (e.g. tumor area vs filtration organs). 
 
3.4 Conclusion 
The Ce6-8PEGA NCs have been shown to be ultra-small and possess superior ROS 
production, compared to encapsulated PAAm-Ce6 NPs. The successful exchange of the targeting 
peptides, from CTP to F3-cys, demonstrates this NC’s chemical flexibility in changing targets. 
The F3-8PEGA-Ce6 NCs also displayed good biocompatibility in vitro and their constituent 
composition, as well as previous biodistribution studies, make us believe that this will remain 
true in vivo. 8PEGA additionally demonstrated clear promise as a molecular imaging agent in 
MRI when coupled with techniques meant to suppress water and fat signals. Overall the F3-
8PEGA-Ce6 presents an attractive universal NC for theranostics (imaging and PDT), from heart 
arrhythmia to cancer, and possibly to other pathologies. The potential benefits of rapid renal 
clearance and of accumulation in early stage tumors, even before angiogenesis, coupled with the 
MRI results, encourage a translation to animal studies.  
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3.6 Materials and Methods 
Materials: Chlorin e6 (Ce6) and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
are sourced from Frontier Scientific. 8PEGA (40kDa) and Bi-PEG (Maleimide-PEG-
Succinimydal Ester, 2kDA) is sourced from Creative PEG Works. F3-Cys peptide 
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) is sourced from SynBioSci. 190 proof 
natured ethanol from Decon Labs. 10kDa and 300kDa filters for Amicon Cells and 10kDa 
centrifugal filters are sourced from Amicon. DMEM [(+) glutamine, sugar, sodium pyruvate), 
penicillin streptomycin, and fetal bovine serum are sourced from Life Technologies. All other 
chemicals sourced from Sigma Aldrich. Acrylamide, 3-(Acryloyloxy)-2-hydroxypropyl 
methacrylate (AHM), aminopropyl methylacrylamide hydrogen chloride salt (APMA), N-
hydroxy succinimide (NHS), N,N'-Dicyclohexylcarbodiimide (DCC), Brij L4, dioctyl 
sulfosuccinate sodium salt (AOT), dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), 
ammonium persulfate (APS), tetramethyl ethylene diamine (TEMED), phosphate buffer saline 
(0.01M, PBS), hexanes, cysteine, anthracene dipropionic acid (ADPA), calcein AM, propidium 
iodide (PI). 
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8PEGA-Ce6 Conjugate: Ce6 is conjugated to 8PEGA via DCC/NHS coupling in DMF.14 
Briefly, 448uL of Ce6 solution (20mg/mL, DMF) is activated with 154.8uL DCC and 172.8uL 
NHS under stirring (20mg/mL, DMF) for 30 minutes. 500mg 8PEGA is solvated in DMF at a 
concentration of 50mg/mL using sonication. Upon solvation, the Ce6 solution is added to the 
8PEGA solution and allowed to stir overnight. The following day, unconjugated Ce6 is removed 
using 50% ethanol/PBS mixture in an Amicon Cell filtration system using a 10kDa membrane. 
After purification, the solvent is exchanged with Millipore ultrapure water, the materials filtered 
using a 0.45um syringe filter, and freeze dried for storage. 
F3-8PEGA-Ce6 Conjugate: 8PEGA-Ce6 was modified with F3 via the same methods 
reported by our lab over the years.15,20-23 After modification with F3-cys, the UV/VIS was then 
taken to ensure that the Ce6 had not aggregated in the process. Briefly, 20mg of Bi-PEG is added 
to 1mL of 8PEGA-Ce6 (20mg/mL, PBS) and stirred for 30 minutes. The solution is then washed 
4x15mintues in PBS using a 10kDa centrifugal filter. The resulting solution is concentrated to 
20mg/mL (by original mass), 22mg of F3-cys is added (220uL, 11mg/110uL DMSO), and left to 
stir over night. The next day, excess of cysteine is added and stirred for 2 hours to cap any 
unreacted maleimide groups. The solution is then filtered again using a 10kDa centrifugal filter 
and millipore ultrapure water, and freeze dried for storage. 
Ce6 Encapsulated Polyacrylamide Nanoparticles (PAAm NPs): Ce6 is encapsulated in 
PAA NPs through a slightly modified previously reported method.17 Briefly, 5mg of Ce6 is 
added to 930uL of PBS and 100uL DMSO with 28mg APMA, 19mg NHS, and 16mg EDC. The 
solution is stirred at 37 oC for 2 hours. Acrylamide and AHM are then added to the solution 
(368mg and 52.6uL, respectively) and sonicated to create a uniform solution. This solution is 
added to a 100mL round bottom flask containing 31mL hexanes, 2.2mL Brij L4, and 1.07g AOT 
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under stirring. The stirring is adjusted to where the generated vortex is just barely touching the 
stir bar (~500 RPM). The contents of the flask are then purged with nitrogen for 15 minutes. 
Nitrogen flow is removed from contact with the flask contents and maintained inside the flask. 
15mg of APS in 100uL of water is added dropwise to initiate polymerization and 100uL of 
TEMED added dropwise to catalyze the process. Polymerization is allowed to proceed for 2 
hours. Hexanes are then removed via rotary evaporation. The resulting contents are re-dispersed 
in ethanol and cleaned using 10x150mL ethanol and 5x150mL Millipore ultrapure water in an 
Amicon Cell using a 300kDa filter. The purified materials are syringe filtered using a 0.45um 
filter and freeze dried for storage. 
Equipment: A Shimadzu UV-1601 UV/Visible Spectrophotometer is used for recording 
and adjusting the optical density (OD) of PAAm-Ce6 NPs. All fluorescence spectra are taken 
using a Fluoromax-3. 
Size Analysis: Size of 8PEGA was characterized through two methods: TEM and NMR. 
To gather images of 8PEGA in its hydrated form, the compound was deposited on a copper grid, 
stained with uranyl acetate, and placed into the chamber while the grid is still wet. This enabled 
reasonable visualization of the low electronically dense 8PEGA by using surface tension to 
maintain its conformation. Size was analyzed via NMR using the Stokes-Einstein equation for 
translational motion (see MRI section for NMR measurements). 
MRI: NMR relaxation times T1, T2 and translational diffusion constant, D, of 8PEGA 
were determined at 25 and 35 °C with a Varian/Agilent 16.4T NMR high resolution spectrometer 
equipped with pulsed field gradients.  T1, T2 and diffusion data were collected with inversion-
recovery, spin-echo, and stimulated-echo pulse sequences, respectively.  
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T1 times were estimated by fitting recovery of longitudinal magnetization to 𝑀𝑧(𝑡) =
𝑀0(1 − 2 exp (−
𝑡
𝑇1
)) where t is the time between the inversion RF pulse and sampling RF 
pulse.  T2 times were estimated by fitted decay of transverse magnetization to 𝑀𝑥𝑦(𝑡) =
𝑀𝑥𝑦(0) exp (−
𝑡
𝑇2
)  where t is the time for formation of the spin echo.  The translation diffusion 
constant D was estimated by fitting the decay of magnetization due to a pair of pulsed magnetic 
field gradients in a stimulate echo experiment to 𝑀𝑥𝑦(𝑏) =  𝑀0exp (−𝑏𝐷) where b is given by 
𝑏(𝐺𝑧 , 𝛿, 𝛥) = (𝛾𝐺𝑧𝛿)
2(𝛥 −
𝛿
3
)  where 𝐺𝑧 amplitude of the applied gradient, 𝛾 is the proton 
gyromagnetic ratio, is the, 𝛿 is the duration of the applied gradient and 𝛥 is the time separation 
between the gradient pair. 
Relaxation times and diffusion constant were estimated by fitting appropriate exponential 
functions to the NMR data using scripts written in Matlab (The Mathworks, Natick, MA). MRI 
was performed with a Varian/Agilent 7T animal imaging system using a 120mm diameter 
shielded gradient set capable of 400mT/m and a 40mm millipede RF coil. The images were 
created with a diffusion-weighted, spin-echo sequence with TR/TE of 500/200ms and b values of 
108 and 1010 s/m2 for Figures 6A and 6B, respectively. 
Reactive Oxygen Species (ROS) Evaluation: We use the so called “k-value” test, a 
method of relatively quantifying the amount of ROS produced (larger k-value = more ROS).12 
The 8PEGA-Ce6 ROS k-value was previously reported at an OD of 0.12 at 661nm.14 To 
establish comparable k-values, the PAAm-Ce6 NPs are normalized to the OD of 8PEGA-Ce6 
reported data (adjusted to OD = 0.12 at 660nm) and the k-value evaluated via the same means as 
previously reported.12,14 Briefly, 80 uL of ADPA (0.3 mg/mL) is added to 2 mL of OD = 0.12 
PAAm-Ce6 NPs in PBS. The fluorescence of ADPA is taken before illumination with 661nm 
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light and recorded at 427nm; this is repeated after every 300 seconds with 661nm illumination. 
The ADPA 427nm data points are then plotted as ln(I/Io) vs. time, where the slope is the 
resulting k-value. 
Cell Culture PDT Test: HeLa 229 cells are chosen as the cancer cell test line due to their 
robust nature. These cells were grown using DMEM culture medium containing 1% PenStrep 
and 10% fetal bovine serum. An arc lamp was used as the excitation source for PDT and control 
tests. Briefly, a 35mm culture dish is seeded with 100,000 cells and incubated with 200 ug/mL 
F3-8PEGA-Ce6 for 2 hours. For the cell live/dead tests the cells are stained using calcein AM 
green. After incubation, the cells are washed 3 times with pre-warmed Dulbecco’s PBS (DPBS) 
and 1mL of pre-warmed colorless DMEM (no serum) is added. A 20 uL solution of propidium 
iodide (1 mg/mL) is added as a necrotic cell death indicator for evaluating the PDT. 
Confocal imaging was performed using an ISS ALBA time-resolved confocal 
microscope, with an IX-81 Olympus microscope body and a U-Plan S-APO 60X 1.2NA water 
immersion objective. A Fianium supercontinuum laser with an acousto-optical filter was used to 
generate picosecond-excitation pulses at a wavelength of 488nm at a repetition rate of 20 MHz. 
Fluorescent emission was separated into two channels by a 592nm shortpass dichroic mirror and 
collected simultaneously through 100um pinholes and a 531 +/- 20nm bandpass filter (calcein 
channel) and a 630 ± 32nm bandpass filter (propidium iodide channel) onto a low noise 
avalanche photodiode.  
Photodynamic therapy was activated using a mercury arc lamp with a 692+/-20nm 
excitation filter, using neutral density filters to adjust the total incident power to 50mW/cm2. 
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Chapter 4: Multifuctional Pluronic Micelles for Choroidal Neovascularization (CNV) 
Treatment 
4.1 Introduction 
The following is in preparation for submission to Future Medicine – Nanomedicine. 
It has been shown in the literature that combining cancer ablating modalities (e.g. 
combinations of chemo, photodynamic therapy, or photothermal therapy)2-7 are more potent than 
any modality that is applied alone. Photodynamic therapy (PDT) and photothermal therapy 
(PTT) are considered the most promising in terms of cell selectivity due to the necessity of 
externally applied light to trigger their cell ablating properties, compared to chemo drugs that are 
always active or radiation therapy that is non-selective.8 Cell selectivity can be further increased 
via delivery of the dyes to cancer cells using targeted nanoparticles (NPs). Combinations of 
PDT/PTT in targeted NPs have already been reported.9,10 
Choroidal Neovascularization (CNV) is a condition that if left untreated in the eyes will 
lead to blindness. Current methods of treatment involve the use of growth factor inhibitors that 
are delivered intravitreally11 or untargeted PDT using Verteporfin (VP).12 Strictly speaking, 
CNV is not a form of cancer since it only involves de-regulated angiogenesis. However, it can be 
considered very similar to cancer since it is an uncontrolled growth of a cell population that leads 
to detrimental biological effects (blindness) and possesses a leaky vasculature.13 This leaky 
vasculature indicates that NP-mediated delivery of photosensitizers (PSs) for PDT or PTT would 
be highly effective due to the Enhanced Permeability and Retention (EPR) effect, the same 
principle and method NPs take advantage of in cancer.14 In addition, as the detrimental tissue is 
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entirely composed of vasculature, there is no danger of hypoxia, and the eye is mostly 
transparent, allowing for highly viable PDT. Cationic liposomes have previously been used to 
encapsulate VP and were shown to have greater PDT efficacy than the free dye.15 
Due to the above information, previously reported pluronic micelles16 containing the 
FDA-approved dyes VP and indocyanine green (ICG) have been designed for improved 
treatment of CNV. Verteporfin will be used for PDT and ICG may induce combined PTT effects 
with PDT, provide photoacoustic imaging, and/or fluorescence imaging. The micelles may also 
be functionalized with polyethylene glycol (PEG) and a cysteine terminated targeting peptide to 
increase accumulation in the anomalous vasculature of CNV.16 
 
4.2 Results 
4.1.1 UV/VIS and Fluorescence of Micelles: Figures 4-1 and 4-2 are UV/VIS spectra of the 
pluronic micelles prepared 1) with VP and ICG separately, 2) with VP and ICG together, and 3) 
the two spectra added together. As their general shapes remain the same, the spectra show that 
the dyes do not interfere with each other, as demonstrated by the simple additive properties of 
the spectra. Filtration of the micelles through a 100 kDa centrifugal filter yielded no loss of 
color, indicating that the dyes are trapped entirely within the micelles. This is further reinforced 
by the red shift of the ICG peak from 780nm to 797nm, a common feature of the dye when 
solvent effects are removed (in this case, via encapsulation in the micelles’ hydrophobic 
interior). In addition, no aggregates seem to be present by a lack of dimer peaks in the UV/VIS. 
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Figure 4-1: Absorption spectra of pluronic micelles in pure water (2mg/mL) containing either VP 
(blue) or ICG (orange) alone and the two spectra added together (grey). Yellow is the spectrum 
of the as-prepared and used micelles. 
Fluorescence spectra of the pluronic micelles containing both VP (Figure 4-2) and ICG (Figure 
4-3) were taken to demonstrate preservation of optical properties. ICG was excited using the red 
shifted 797nm peak. Porphyrin dyes are known to have exceptionally small stokes shifts, and so 
to capture the peak fluorescence point VP was excited at 400nm.  
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Figure 4-2: Fluorescence spectra of VP in pluronic micelles containing both VP and ICG. 
Concentration is 1mg/mL micelles in pure water. Excited at 400 nm. 
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Figure 4-3: Fluorescence spectra of ICG in pluronic micelles containing both VP and ICG. 
Concentration is 1mg/mL micelles in pure water. In correspondence with the red shifted 
absorption, the fluorescence is also red shifted ~20nm. Excited at 797nm. 
 
4.2.2 Characterization of Micelle Size: NP related systems can have their sizes characterized 
through either dynamic light scattering (DLS) or TEM. In this case, both must be employed. 
DLS typically uses a 658nm line, which is absorbed by the micelles, making characterization of 
the dye containing micelles by this method impossible. Therefore, DLS of blanks were taken 
(Figure 4-4) and compared with wet TEMs of the dye containing micelles (Figure 4-5). 
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Figure 4-4: DLS measurement of blank micelles at 2mg/mL in pure water. Average size is found 
to be ~29nm. 
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Figure 4-5: Wet TEM of pluronic micelles containing both VP and ICG. A) Wide field view of 
micelles on a copper grid. B) Zoomed in on a well resolved single micelle. Size distribution is 
predominantly in the range of 10-20nm. 
B 
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4.2.3 Cytotoxicity of Micelles: Before proceeding to confocal microscopy studies, the 
biocompatibility of the as prepared micelles containing both VP and ICG was tested via MTT 
assay. HeLa cells were chosen as the test line and incubated overnight to allow adequate time for 
interaction with the micelles. The micelles displayed no toxicity at the high concentration of 
200ug/mL, as shown by the essentially identical cell populations between the control and test 
lines after incubation (Figure 4-6). 
 
Figure 4-6: MTT assay of HeLa cells incubated with micelles containing both VP and ICG 
overnight. 
 
4.2.4 Confocal Microscopy Evaluation of PDT: HeLa cells were taken for confocal 
microscopy to study the effects on the cells when initiating PDT at 690nm (Figure 4-7) or PTT at 
780nm (Figure 4-8). Figures 4-7A/8A are cytosolic stain calcein AM fluorescence images of the 
cells prior to treatment and Figures 4-7B/8B are calcein AM after treatment. Membrane 
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impermeable propidium iodide (PI) stain was also employed to evaluate the damage to HeLa 
cells (Figures 4-7C/8C); no PI fluorescence is observable prior to treatment. 
  
 
Figure 4-7: Confocal microscopy images of HeLa cells before and after VP-mediated PDT from 
VP/ICG containing micelles. A) Calcein AM fluorescence of cells prior to PDT. B) Calcein AM 
fluorescence after 10min of PDT (50mW/cm2, 690nm). C) PI fluorescence images after PDT. 
A B 
C 
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Figure 4-8: Confocal microscopy images of HeLa cells before and after ICG-mediated PTT from 
VP/ICG containing micelles. A) Calcein AM fluorescence of cells prior to PTT. B) Calcein AM 
fluorescence after 30min PTT (500mW/cm2, 780nm). C) PI fluorescence images after PTT. 
 
4.3 Discussion 
CNV is a difficult to treat condition due to a lack of existing methodologies that suitably 
target it while being highly selective. However, the anomalous and leaky vasculature make NP-
mediated treatments an attractive improvement to resolving the condition.  
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Micelles constructed of the pluronics F68 and P123 very efficiently encapsulated the 
FDA-approved dyes ICG and VP when generated through the thin film rehydration method. The 
dyes VP and ICG were chosen for several reasons: 1) VP is specifically the PS FDA-approved 
for treatment of CNV via PDT, 2) ICG has also received FDA approval for fluorescence imaging 
in humans and absorbs deep tissue penetrating 780nm light, 3) ICG has been previously 
employed as either a photo-acoustic agent17 or PTT agent.18 
The absorption properties of the dyes are preserved and confirmed to be independent of 
each other by their simple additive nature (Figure 4-1). In addition, the dyes are still fluorescent, 
indicating that VP will still produce reactive oxygen species (ROS, Figure 4-2) and ICG will still 
function as a fluorescent imaging agent (Figure 4-3). ICG remaining fluorescent will not affect 
its ability to function as a photo-acoustic agent, as fluorescent ICG has been shown to be a 
capable agent in photo-acoustics already.19 The absorption spectrum of the micelles used 
hereafter in vitro are shown in Figure 4-1 (yellow).  
Size analysis of this system is difficult because they are micelles (problematic in TEM) 
and are broadband absorbers (prevent use of DLS). Therefore, a mixture of the two methods 
under modified conditions were necessary. Micelles with no dye enabled DLS (Figure 4-4) and 
TEM was measurable of micelles with both dyes by placing the copper grid into the microscope 
while wet; wet EM as used here took advantage of surface tension to allow some micelles on the 
grid to maintain their confirmation after the water evaporates in the vacuum chamber (Figure 4-
5). It is found that the size of the micelles by DLS is ~29nm. TEM matches this well by ranging 
the 28 measured micelles to be between 10-20nm; it is expected that the micelles would be 
smaller by TEM, because though their structures are maintained by the surface tension, it is 
expected that the PEG blocks of the chain copolymer would still shrink somewhat from the 
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dehydration. The small size found here would benefit PDT in vitro due the enhanced surface area 
to volume ratio. 
TEMs were taken in a two-week gap to explore their long-term stability. It is found that 
they are stable for at least two weeks when stored at 20mg/mL concentration. However, if they 
are stored at a dilute concentration of 1mg/mL for the same length of time, some degradation is 
observed. This is an expected result, as micelles form based on a concentration dependence, and 
so while they will be stable for a time at dilute working concentrations (i.e. reactions, in vitro), 
long term storage (weeks scale) should yield degradation. 
To ensure viability in animal models, the cyto-toxicity of the micelles were tested via 
MTT assay (Figure 4-6). A virtual lack of any toxicity is observed in the tested HeLa cells at the 
high concentration of 200ug/mL, indicating that their application to animals, and eventually 
humans, should not pose any significant health concerns. In addition, F68 and P123 are materials 
composed of polypropylene glycol (PPG) and PEG, which are biodegradable, and so should 
quickly clear animals after treatment.  
HeLa cells taken for testing PDT and PTT properties of the micelles showed significant 
promise. A very mild and low energy dosage of 690nm light to initiate PDT from VP resulted in 
the death of the tested HeLa cells, as shown by the significant decrease of calcein AM 
fluorescence due to loss of cytosolic contents (Figures 4-7A/B). ICG demonstrated similar 
effects under the in vivo safe energy dosage of 500mW/cm2 (Figures 4-8A/B). 
PI staining was additionally carried out to demonstrate the effects occurring were photo-
mediated by the dyes, as PI is a membrane impermeable substance; for any staining to occur, 
physical rupture of the cell membranes must occur (Figures 4-7C/8C). 
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PDT was very quickly initiated and completed within 10min, however it should be noted 
that PTT required a substantially longer illumination period of 30min to occur. Given such a 
large time dosage was required, it would probably be desirable to increase the loading of the ICG 
to modulate the heating rate of the cells. However, this may also correspondingly decrease the 
PDT viability by VP due to transfer of excited state energy via FRET to ICG, quenching ROS 
production. This was shown to occur in liposomes containing the dyes Chlorin e6 and ICG.20 
PTT is also known to traditionally only cause necrosis in treated cells, leading to inflammation of 
the affected areas, which may be better off avoided in this case since the eyes are the target 
tissue.20 Therefore, rather than performing PTT alone, it should always be in conjunction with 
PDT, where the treatment affects may be more quickly applied (combined PDT/PTT is known to 
be more efficient than either modality separately), achieving apoptosis with greater propensity or 
limit its role to imaging alone. 
Although not performed here, F68 may be derivatized to be amine terminated, allowing 
for the grafting of PEG onto the micelles surfaces to increase blood circulation time and double 
as a molecular anchor for CNV targeting agents (e.g. RGD).16,22 
 
4.4 Conclusion 
Targetable, biocompatible micelles constructed of the pluronics F68 and P123 were 
successfully generated, encapsulating the FDA-approved dyes VP and ICG. Both dyes were 
capable of separately yielding cell death through PDT (VP) or PTT (ICG). ICG may also 
effectively function as an imaging agent through either fluorescence or photo-acoustics. These 
micelles are expected to enable highly selective treatment and imaging of CNV. 
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4.6 Experimental 
Materials: Verteporfin is sourced from Active Biochem. USP Reference Standard 
Cardiogreen, Pluronic F68, Propdium Iodide (PI), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), dimethylsulfoxide (DMSO), and methanol (99.8%, 
anhydrous) are sourced from Sigma Aldrich. Pluronic P123 is sourced from BASF. Calcein AM 
is sourced from Invitrogen and methylene chloride from Fisher Chemical. 
Micelle Preparation: Micelles of pluronic F68 and P123 are constructed using a 
previously reported protocol.16 Briefly, 84mg F68, 116mg P123, and 1.6mg VP are suspended in 
5mL of methylene chloride in a 50mL round bottom flask. 500ug of cardiogreen in 1mL 
methanol is then added to the flask. The solvents are then removed using rotary evaporation to 
form a thin film and the contents allowed to sit overnight in a hood to ensure total removal of 
methylene chloride and methanol. The thin film is then rehydrated using 10mL of pure water and 
ultrasonication to form the micelles. The micelles are then filtered using a 0.45um polyether 
sulfone membrane. The shelf-life of the final suspension (20mg/mL micelles) is greater than 2 
weeks as confirmed by TEMs of before and after. 
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Equipment: A Shimadzu UV-1601 UV/Visible Spectrophotometer is used for all 
absorption spectra. A Fluoromax 3 is used for all fluorescence spectra. Cell viability from MTT 
assay was measured using an Anthos 2010 plate reader. 
Size Analysis: Micelles were characterized by TEM and DLS. Briefly, micelles 
containing no dye were used for DLS at a concentration of 2mg/mL in pure water. TEMs were 
taken through the Microscopy and Image Analysis Laboratory at the University of Michigan. 
TEM was carried out by depositing micelles on a copper grid and placing into the vacuum 
chamber while still wet. The purpose is that surface tension will cause the micelles to maintain 
their structure when the water evaporates, preventing some from simply collapsing due to the 
loss of hydration. 
MTT Assay: A 24-well plate is seeded with 12,500 cells per well (4x2) and 600uL of 
DMEM (10% FBS, 1% Pen Strep). The cells are allowed to settle for 24 hours, and then 4 of the 
wells are seeded with 200ug/mL micelles and incubated overnight. After incubation, all media is 
removed and fresh DMEM containing no FBS is added. 60uL of 0.45um filtered 5mg/mL MTT 
in pure water is then added and allowed to react for 4 hours. Cell media is then carefully 
removed and 600uL of DMSO is added to each plate and allowed to sit for 90min. The 
absorption of each well is then measured to determine the cell populations’ viability. 
PDT/PTT Confocal Microscopy: A confocal glass bottom plate is seeded with 100,000 
cells and 1mL of 200ug/mL micelles in DMEM (10% FBS, 1% Pen Strep) and incubated 
overnight. The cells are stained with calcein AM, washed 3 times with DPBS, and 1mL of media 
solution containing 10mM HEPES, 2mM CaCl2, and 150mM NaCl at pH 7.4, added with 20uL 
of 1mg/mL PI. 
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Confocal imaging was performed using an ISS ALBA time-resolved confocal 
microscope, with an IX-81 Olympus microscope body and a U-Plan S-APO 60X 1.2NA water 
immersion objective. A Fianium supercontinuum laser with an acousto-optical filter was used to 
generate picosecond-excitation pulses at a wavelength of 488 nm at a repetition rate of 20 MHz. 
Fluorescent emission was separated into two channels by a 592 nm shortpass dichroic mirror and 
collected simultaneously through 100 um pinholes and a 531 +/- 20 nm bandpass filter (calcein 
channel) and a 630 ± 32 nm bandpass filter (propidium iodide channel) onto a low noise 
avalanche photodiode.  
Photodynamic therapy was activated using a mercury arc lamp with a 692+/-20 nm 
excitation filter, using neutral density filters to adjust the total incident power to 50mW/cm2. 
Photothermal therapy was similarly initiated using a standard ICG filter set and the power 
adjusted to 500mW/cm2. 
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Chapter 5: Conclusions and Future Directions 
5.1 Conclusions 
PDT is a highly attractive method of dealing with biological ailments due to its ability to 
provide cell-specific ablation; only cells that are illuminated, and contain a PS, will experience 
therapeutic effects.1 The advent of NP-mediated delivery has further heightened the cell 
specificity by providing a means of targeting dyes to specific biological locales and protecting 
them against non-specific protein adsorption/interactions.2 In addition to this, great pains have 
been exercised to ensure that these materials are biologically compatible over the long term.3 
When combined with fiber optics, which have existed for over 20 years, sub-surface tumors may 
be easily targeted and treated.4 However, even with these advancements, there has been little 
widespread adoption within the clinic. There are a number of possible reasons for this: 1) low 
business incentives to produce and sell due to lack of IP protection, 2) a tendency of clinicians to 
“stick to their guns” and thus take little notice of advancements in their field or are hesitant to 
adopt new methods, 3) lack of expertise in the industry to help drive adoption from work bench 
to work place, 4) lack of interest due to perceived shortcomings, or 5) insufficient clinical human 
data on how to properly apply the systems and long term data to promote FDA approval. 
The pharma industry is heavily centered on being able to identify a viable market and 
produce a solution that generates significant profit. With respect to the above mentioned, (1) 
through (3) are changes that must come from within the industry. However, those changes can be 
influenced from the lab by providing materials that show clear cut results and efficacy that 
cannot be competed with when paired against traditional means of treatments in cancer (chemo, 
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radiation therapy, invasive surgery).3 Therefore, the bulk of this presented work has focused on 
identifying the currently perceived advantages/limits of PDT methodologies and designing 
systems to optimize them in their specific applications, (4). 
Synthesis of PAAm-Ce6 NPs helped to identify the relative PDT aggression of the 
classically employed dye Ce6 in NPs vs MB-NPs. In reporting this, it may be better understood 
in what PSs to choose for PDT based on what results a clinician may wish to see. For example, if 
a rapid tissue response is needed in controlling the tumor progression, then Ce6 would be an 
optimal choice, or if the area of operation requires a gentler treatment that favors apoptosis over 
necrosis to avoid inflammation (e.g. in the brain), MB would be preferable. 
8PEGA has clearly presented itself as an attractive material for its biocompatibility, 
potential as a molecular agent in MRI, optimization in ROS production, and flexibility in 
targeting different ailments. In effect, 8PEGA represents a system that may be flexibly applied 
and optimize PDT across a variety of diseases. 
Pluronic based micelles have clearly demonstrated an ability to encapsulate VP and ICG 
to ablate cells, enabling the potential for their targeted delivery in vivo to treat CNV and 
simultaneously avoid the issue of collateral tissue damage that is present in the current use of VP 
alone in the clinic. This is an important step to providing efficient treatment for a disease that is 
predominantly treated by intravitreal delivery of antigrowth factors, which only treat the 
condition as opposed to stopping it. 
It is hoped that the reported data here may further drive interest to clinically adopt NP-
mediated PDT as a methodology in surface/sub-surface cancer and cancer-like diseases. 
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5.2 Future Directions 
 Having shown in cell work the efficacy for the above systems (F3-8PEGA-Ce6 and 
VP/ICG pluronic micelles), they should now be translated to animal models. Specifically, the F3-
8PEGA-Ce6 animal work should focus on demonstrating accumulation in and imaging of tumor 
tissue, as well as determining renal clearance of animals. VP/ICG micelles will be used in rabbit 
models where CNV has been artificially induced to demonstrate their efficacy, selective 
accumulation, and ablation of the anomalous vasculature. A combination of fluorescence, photo-
acoustic, or optical computational topography images will be used to visualize the effects and 
progression of the condition with PDT treatment. 
It is believed that further optimization of the NPs presented above would also be 
accomplished by using long wavelength NIR dyes. In addition, establishing preferred protocols 
of PDT application in non-xenograft models will be necessary to allow proper patient treatment. 
 
5.2.1 PS Selection and Design 
 With respect to PS design for PDT, porphyrins are commonly used a base material in 
synthetic investigation due to their excellent ROS production properties. However, there has not 
been a significant number of reported derivatives with successful shifting of excitation and 
emission deep into the NIR. One current example would be TOOKAD Soluble (Figure 5-1).5 
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Figure 5-1: TOOKAD Soluble structure. Lambda max = ~763nm. Reproduced from reference 5. 
 Notably, TOOKAD Soluble contains a coordinated palladium atom. Coordinating metals 
have been thoroughly explored in the literature for increasing ROS production through the heavy 
atom effect.6 
 It has been reported in Dr. Ravindra K. Pandey’s book “Handbook of Photodynamic 
Therapy” that the resonance wavelength of porphyrins can also be influenced through 
modification of the central porphyrin ring.7 This has been substantiated in the literature8,9 and has 
even been investigated using ring expansions that contain hetero atoms, like sulfur.10 Good ROS 
production has been shown for these structures.11 It is therefore believed that work should be 
done on finding a careful balance of porphyrin ring expansion, heteroatom replacement, 
coordinating metals, and R group choice to tune the absorption, solubility, and ROS generation 
properties to sufficiently enhance efficacy of porphyrin PSs for subsurface tumor PDT treatment. 
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5.2.2 Understanding Biological Complexity involved in Applying PDT 
 Currently, enabling PDT treatment of sub-surface tumors is possible even without deep 
NIR absorbing PSs, as fiber optics can easily provide the necessary light to many body 
locations.3 A very important issue is dealing with case-by-case differences of how tumors grow, 
proliferate, and consume their nutrients. This specifically refers to how, in each patient, a tumor 
may be of different size, shape, chemical content or location (relative to vasculature and 
biological environment). For example, a tumor that is highly networked in the tissue may be less 
prone to hypoxia when compared to one that is a single large mass. Therefore, future studies 
should place emphasis on the general shape and location and oxygen content of a tumor, to 
optimize how best the PDT should be applied; creating a library of data on examined tumor 
models and measuring their levels of hypoxia photo-acoustically would be highly beneficial. 
 There are three potential methods of suitably applying PDT: 1) sequential administration 
of PDT to progressively shave down the tumor mass, 2) increasing tissue oxygenation (whether 
by additives that increase tissue oxygenation like sodium salt transcrocetin12 or breathing oxygen 
rich air), or 3) coupling with PTT.  
Combinations of any of these three methods may be advantageous. For example, a tumor 
that is a single large mass may require sequential doses of PDT to completely remove it (each 
dose would expose sub-layers of the tumor, which would subsequently re-oxygenate). But, fewer 
subsequent doses may be needed and faster total ablation accomplished with heightened 
oxygenation. Likewise, PTT may remove the limitation of low oxygen deeper within the tumor 
mass, due to its effect being independent of oxygen concentration, but may also be limited based 
on the biological environment; PTT classically induces necrosis, leading to inflammation of 
tissue that would be better avoided in certain areas, like the brain. 
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Thus, future work on the evaluation of best practices and application methods is 
exceptionally important. This should encompass using any one of the three above approaches 
singularly or applying them in any combination and studying how the responses are correlated. 
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